Fosamax Exposure Linked to Osteonecrosis of the Jaw: Mechanisms and Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Occupational Concern

For decades, public health communication has centered on general wellness and the science behind common medical interventions. This legacy framework has effectively guided broad audiences through foundational concepts in disease prevention and treatment safety. Within this context, discussions of medication side effects have typically remained at a population level, emphasizing statistical risks and standard clinical guidelines. However, as scientific inquiry deepens, the focus naturally narrows from general health principles to specific, high-stakes exposure scenarios. The transition from a broad health information paradigm to a more targeted occupational concern requires acknowledging that certain pharmaceutical exposures carry distinct implications for workplace safety. In particular, the shift from general patient education to professional exposure assessment becomes critical when considering agents with known potential for serious adverse outcomes. This pivot does not involve detailing biological mechanisms or citing specific evidence; rather, it reframes the conversation around the practical realities of occupational contact. The same rigorous approach that once served general health literacy now must be applied to evaluating how specific chemical exposures—such as those encountered in manufacturing, handling, or administration settings—may pose unique risks to workers. By moving from a universal health lens to a focused occupational perspective, we can better address the nuanced responsibilities of protecting those whose daily environments involve sustained contact with potent therapeutic compounds.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on this occupational perspective, we now examine a specific pharmaceutical agent: Fosamax (alendronate), a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its use has been associated with a serious adverse effect: osteonecrosis of the jaw (ONJ). This condition involves bone death in the jaw, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ typically involves exposed necrotic bone in the maxillofacial region, often following dental procedures such as tooth extraction, dental implants, or boney surgery (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Diagnosis is based on clinical examination and imaging, with delayed healing of oral wounds being a key indicator. The condition can lead to significant morbidity, including pain, infection, and difficulty eating.

Mechanistic Pathways and Evidence from Animal Studies

Mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but research provides insights into jawbone-specific responses. Multiscale characterization of jawbone in animal models treated with bisphosphonates, including alendronate (the active ingredient in Fosamax), has been conducted to understand bone-related complications (https://pubmed.ncbi.nlm.nih.gov/40345077). In estrogen-deficient rats, treatments with bisphosphonate (alendronate) were studied to determine effects on jawbone, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077). This research suggests that bisphosphonate therapy alters jawbone properties, potentially contributing to ONJ development. The current multiscale characterization of jawbone provides comprehensive information that can help better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077). Known risk factors for ONJ include invasive dental procedures, diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Causation Considerations and Clinical Management

Causation-related considerations for affected patients involve establishing a temporal relationship between Fosamax exposure and ONJ onset. The timeline between exposure and documented harm can vary, with symptoms appearing from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients who develop ONJ, discontinuation of Fosamax is recommended, and management may involve dental evaluation and treatment of infection. The prescribing information advises discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under "Warnings and Precautions" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and describes associated risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the time to onset of symptoms varied from one day to several months after starting the drug, and most patients had relief of symptoms after stopping (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, evidence supports a link between Fosamax exposure and osteonecrosis of the jaw, with mechanistic insights from animal studies and clinical risk factors identified. Warnings in the prescribing information address this risk, but the variable onset and potential for recurrence upon rechallenge highlight the need for careful monitoring in patients receiving bisphosphonate therapy.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and what is it used for?

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?

Osteonecrosis of the jaw (ONJ) is a condition involving bone death in the jaw, often presenting as exposed necrotic bone in the maxillofacial region. ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies, poor oral hygiene, and longer duration of bisphosphonate use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

What are the symptoms and diagnosis of ONJ?

Symptoms include exposed necrotic bone in the jaw, pain, infection, and difficulty eating. Diagnosis is based on clinical examination and imaging, with delayed healing of oral wounds being a key indicator (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

How is ONJ managed in patients taking Fosamax?

Management includes discontinuation of Fosamax, dental evaluation, and treatment of infection. The prescribing information advises discontinuing use if severe symptoms develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.